PMV Pharma reports Q1 net loss $19.1M; PC14586 trial advances

PMV Pharmaceuticals, Inc.

2023-Q3 EPS reported -$0.42

Net loss Q1 2023 $19.1M vs $18.4M Q1 2022; cash & equivalents $229.4M.
R&D expenses $15.1M (up from $11.8M) due to increased clinical costs for PC14586.
Phase 1/2 PYNNACLE study of PC14586 ongoing; next update expected in 2H 2023.
Enrollment commenced in combination arm of PC14586 with KEYTRUDA (pembrolizumab).
Net cash used in operations $15.0M vs $18.0M in prior year period.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PMV Pharmaceuticals, Inc. reported the first quarter ended March 31, 2023 results: net income Net loss for the quarter ended March 31, 2023, was $19.1 million.

Period: the first quarter ended March 31, 2023
Net income: Net loss for the quarter ended March 31, 2023, was $19.1 million
Result: reported results

Exact text from the filing

PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2023.

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

PMV Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020097

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.